Table 1.
Placebo n = 60 | Efpeglenatide 4 mg once weekly n = 59 | Efpeglenatide 6 mg once weekly n = 59 | Efpeglenatide 6 mg once every 2 wk n = 59 | Efpeglenatide 8 mg once every 2 wk n = 58 | All N = 295 | |
---|---|---|---|---|---|---|
Age, years | 43.7 (11.8) | 42.9 (12.1) | 43.0 (13.0) | 43.3 (12.5) | 43.9 (9.2) | 43.4 (11.7) |
Female, n (%) | 44 (73.3) | 41 (69.5) | 46 (78.0) | 43 (72.9) | 51 (87.9) | 225 (76.3) |
Race, n (%) | ||||||
White | 39 (65.0) | 41 (69.5) | 37 (62.7) | 45 (76.3) | 39 (67.2) | 201 (68.1) |
Black or African‐American | 16 (26.7) | 12 (20.3) | 11 (18.6) | 8 (13.6) | 13 (22.4) | 60 (20.3) |
Asian | 3 (5.0) | 4 (6.8) | 8 (13.6) | 5 (8.5) | 5 (8.6) | 25 (8.5) |
Other | 2 (3.3) | 2 (3.4) | 3 (5.1) | 1 (1.7) | 1 (1.7) | 9 (3.1) |
Ethnicity, n (%) | ||||||
Hispanic or Latino | 7 (11.7) | 4 (6.8) | 10 (16.9) | 7 (11.9) | 6 (10.3) | 34 (11.5) |
Not Hispanic or Latino | 53 (88.3) | 55 (93.2) | 49 (83.1) | 52 (88.1) | 52 (89.7) | 261 (88.5) |
Weight, kg | 97.5 (12.1) | 100.8 (19.3) | 101.7 (19.4) | 99.5 (18.4) | 95.6 (13.3) | 99.0 (16.8) |
BMI, kg/m2 | 34.9 (3.2) | 35.2 (4.5) | 36.3 (4.4) | 35.6 (4.8) | 35.2 (3.9) | 35.4 (4.2) |
BMI 27 to <30 kg/m2, n (%) | 2 (3.3) | 5 (8.5) | 3 (5.1) | 2 (3.4) | 3 (5.2) | 15 (5.1) |
BMI ≥30 kg/m2, n (%) | 58 (96.7) | 54 (91.5) | 56 (94.9) | 57 (96.6) | 55 (94.8) | 280 (94.9) |
Waist circumference, cm | ||||||
Women | 107.0 (10.1) | 107.1 (10.2) | 110.5 (13.4) | 106.8 (10.8) | 108.7 (11.1) | 108.1 (11.2) |
n | 44 | 41 | 46 | 43 | 51 | 225 |
Men | 115.8 (9.7) | 115.8 (14.3) | 116.9 (11.9) | 117.2 (11.3) | 110.3 (10.3) | 115.8 (11.7) |
n | 16 | 18 | 13 | 16 | 7 | 70 |
HbA1c, mmol/mol | 36.4 (4.4) | 36.1 (4.0) | 35.3 (4.7) | 36.9 (3.5) | 35.9 (4.2) | 36.1 (4.2) |
HbA1c, % | 5.5 (0.4) | 5.5 (0.4) | 5.4 (0.4) | 5.5 (0.3) | 5.4 (0.4) | 5.5 (0.4) |
FPG, mmol/L | 5.3 (0.6) | 5.2 (0.7) | 5.3 (0.6) | 5.4 (0.7) | 5.3 (0.5) | 5.3 (0.6) |
Data are mean (SD) unless otherwise stated.
Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin.